IMNN-001 is under clinical development by Imunon and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMNN-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IMNN-001 overview

GEN-1 (EGEN-001) is under development for the treatment of epithelial ovarian cancer, glioblastoma multiforme (brain cancer), fallopian tube cancer, peritoneal cancer, high-grade serous adenocarcinoma, endometrioid adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma and mixed epithelial carcinoma. It is administered intraperitoneally. The therapeutic candidate comprises DNA plasmid encoding IL-12 p35 and p40 genes. It is developed based on the TheraPlas delivery technology, an IL-12 DNA nucleic acid plasmid vector encased in a nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein. It was also under development for colorectal cancer.

Imunon overview

Imunon, formerly Celsion is a clinical-stage oncology company with a focus on developing a portfolio of new cancer treatments, including directed chemotherapies, RNA and DNA based therapies and immunotherapies. The company develops drugs using its three platform technologies including Lysolipid Thermally Sensitive Liposomes (LTSL), TheraPlas and TheraSilence. Its lead product candidate ThermoDox is a proprietary form of doxorubicin based LTSL technology in Phase III clinical trial for the treatment of primary liver cancer. It is also developing a pipeline of targeted therapeutic agents for cancer. Imunon is headquartered in Lawrenceville, New Jersey, the US.

For a complete picture of IMNN-001’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.